Drug
Tasimelteon
Tasimelteon: highest development phase Phase 3, developed by Vanda Pharmaceuticals. 15 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| tasimelteon NCT01218789 | Phase 3 | Non 24 Hour Sleep Wake Disorder |
| tasimelteon NCT01429116 | Phase 3 | Non-24-Hour Sleep-Wake Disorder |
| Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension NCT05361707 | Phase 3 | Autism Spectrum Disorder |
| Tasimelteon NCT06701396 | Phase 3 | Sleep Wake Disorders |
| Tasimelteon Oral Suspension NCT06953869 | Phase 3 | Insomnia Disorder |
| Tasimelteon NCT04652882 | Phase 3 | Sleep Wake Disorders |
| tasimelteon NCT01163032 | Phase 3 | Non-24-Hour Sleep-Wake Disorder |
| tasimelteon NCT01428661 | Phase 2/3 | Major Depressive Disorder |
| tasimelteon NCT02231008 | Phase 2/3 | Smith-Magenis Syndrome |
| Tasimelteon NCT01477619 | Phase 1 | Healthy Volunteers |
| Tasimelteon NCT01526746 | Phase 1 | Renal Impairment |
| tasimelteon NCT01578057 | Phase 1 | Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol |
| tasimelteon NCT01637636 | Phase 1 | Healthy |
| Tasimelteon NCT06323655 | Phase 1 | Healthy Volunteers |
| Tasimelteon NCT01402076 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Tasimelteon on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.